Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma von Locke, Frederick L., Miklos, David B., Jacobson, Caron A., Perales, Miguel-Angel, Kersten, Marie-José, Oluwole, Olalekan O., Ghobadi, Armin, Rapoport, Aaron P., McGuirk, Joseph, Pagel, John M., Muñoz, Javier, Farooq, Umar, van Meerten, Tom, Reagan, Patrick M., Sureda, Anna, Flinn, Ian W., Vandenberghe, Peter, Song, Kevin W., Dickinson, Michael, Minnema, Monique C., Riedell, Peter A., Leslie, Lori A., Chaganti, Sridhar, Yang, Yin, Filosto, Simone, Shah, Jina, Schupp, Marco, To, Christina, Cheng, Paul, Gordon, Leo I., Westin, Jason R.

Volltext

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma von Locke, Frederick L., Rossi, John M., Neelapu, Sattva S., Jacobson, Caron A., Miklos, David B., Ghobadi, Armin, Oluwole, Olalekan O., Reagan, Patrick M., Lekakis, Lazaros J., Lin, Yi, Sherman, Marika, Better, Marc, Go, William Y., Wiezorek, Jeffrey S., Xue, Allen, Bot, Adrian

Volltext

Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States von Oluwole, Olalekan O, Ray, Markqayne D, Zur, Richard M, Ferrufino, Cheryl P, Doble, Brett, Patel, Anik R, Bilir, S Pinar

Volltext

Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas von Riedell, Peter A., Hwang, Wei-Ting, Nastoupil, Loretta J., Pennisi, Martina, McGuirk, Joseph P., Maziarz, Richard T., Bachanova, Veronika, Oluwole, Olalekan O., Brower, Jamie, Flores, Oscar A., Ahmed, Nausheen, Schachter, Levanto, Bharucha, Kharmen, Dholaria, Bhagirathbhai R., Schuster, Stephen J., Perales, Miguel-Angel, Bishop, Michael R., Porter, David L.

Volltext

Cutaneous Manifestations and Management of Hematologic Neoplasms von Oluwole, Olalekan O., MD MPH, Zic, John A., MD, Douds, Jonathan J., MD, Thompson, Mary Ann, MD PhD, Greer, John P., MD

Volltext

Clinical experience of CAR T cell therapy in lymphomas von Oluwole, Olalekan O.

Volltext

Role of bridging therapy during chimeric antigen receptor T cell therapy von Bhaskar, Shakthi T., Dholaria, Bhagirathbhai R., Sengsayadeth, Salyka M., Savani, Bipin N., Oluwole, Olalekan O.

Volltext

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results von Mailankody, Sham, Matous, Jeffrey V., Chhabra, Saurabh, Liedtke, Michaela, Sidana, Surbhi, Oluwole, Olalekan O., Malik, Shahbaz, Nath, Rajneesh, Anwer, Faiz, Cruz, Jose Carlos, Htut, Myo, Karski, Erin E., Lovelace, Wade, Dillon, Myles, Butz, Eric, Ying, Wendy, Balakumaran, Arun, Kumar, Shaji K.

Volltext

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial von Neelapu, Sattva S., Dickinson, Michael, Munoz, Javier, Ulrickson, Matthew L., Thieblemont, Catherine, Oluwole, Olalekan O., Herrera, Alex F., Ujjani, Chaitra S., Lin, Yi, Riedell, Peter A., Kekre, Natasha, de Vos, Sven, Lui, Christine, Milletti, Francesca, Dong, Jinghui, Xu, Hairong, Chavez, Julio C.

Volltext

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study von Shah, Bijal D, Ghobadi, Armin, Oluwole, Olalekan O, Logan, Aaron C, Boissel, Nicolas, Cassaday, Ryan D, Leguay, Thibaut, Bishop, Michael R, Topp, Max S, Tzachanis, Dimitrios, O'Dwyer, Kristen M, Arellano, Martha L, Lin, Yi, Baer, Maria R, Schiller, Gary J, Park, Jae H, Subklewe, Marion, Abedi, Mehrdad, Minnema, Monique C, Wierda, William G, DeAngelo, Daniel J, Stiff, Patrick, Jeyakumar, Deepa, Feng, Chaoling, Dong, Jinghui, Shen, Tong, Milletti, Francesca, Rossi, John M, Vezan, Remus, Masouleh, Behzad Kharabi, Houot, Roch

Volltext

Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies von Baik, Alan H., Oluwole, Olalekan O., Johnson, Douglas B., Shah, Nina, Salem, Joe-Elie, Tsai, Katy K., Moslehi, Javid J.

Volltext

Chimeric antigen receptor T‐cell therapy: Challenges and framework of outpatient administration von Gatwood, Katie S., Dholaria, Bhagirathbhai R., Lucena, Mariana, Baer, Brittney, Savani, Bipin N., Oluwole, Olalekan O.

Volltext

Chimeric antigen receptor‐T cell therapies: The changing landscape von Sengsayadeth, Salyka M., Dholaria, Bhagirathbhai R., Savani, Bipin N., Oluwole, Olalekan O.

Volltext

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma von Neelapu, Sattva S., Jacobson, Caron A., Oluwole, Olalekan O., Munoz, Javier, Deol, Abhinav, Miklos, David B., Bartlett, Nancy L., Braunschweig, Ira, Jiang, Yizhou, Kim, Jenny J., Zheng, Lianqing, Rossi, John M., Locke, Frederick L.

Volltext

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma von Neelapu, Sattva S., Jacobson, Caron A., Ghobadi, Armin, Miklos, David B., Lekakis, Lazaros J., Oluwole, Olalekan O., Lin, Yi, Braunschweig, Ira, Hill, Brian T., Timmerman, John M., Deol, Abhinav, Reagan, Patrick M., Stiff, Patrick, Flinn, Ian W., Farooq, Umar, Goy, Andre H., McSweeney, Peter A., Munoz, Javier, Siddiqi, Tanya, Chavez, Julio C., Herrera, Alex F., Bartlett, Nancy L., Bot, Adrian A., Shen, Rhine R., Dong, Jinghui, Singh, Kanwarjit, Miao, Harry, Kim, Jenny J., Zheng, Yan, Locke, Frederick L.

Volltext

Single-cell analysis by mass cytometry reveals metabolic states of early-activated CD8+ T cells during the primary immune response von Levine, Lauren S., Hiam-Galvez, Kamir J., Marquez, Diana M., Tenvooren, Iliana, Madden, Matthew Z., Contreras, Diana C., Dahunsi, Debolanle O., Irish, Jonathan M., Oluwole, Olalekan O., Rathmell, Jeffrey C., Spitzer, Matthew H.

Volltext

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma von Westin, Jason R., Oluwole, Olalekan O., Kersten, Marie José, Miklos, David B., Perales, Miguel-Angel, Ghobadi, Armin, Rapoport, Aaron P., Sureda, Anna, Jacobson, Caron A., Farooq, Umar, van Meerten, Tom, Ulrickson, Matthew, Elsawy, Mahmoud, Leslie, Lori A., Chaganti, Sridhar, Dickinson, Michael, Dorritie, Kathleen, Reagan, Patrick M., McGuirk, Joseph, Song, Kevin W., Riedell, Peter A., Minnema, Monique C., Yang, Yin, Vardhanabhuti, Saran, Filosto, Simone, Cheng, Paul, Shahani, Shilpa A., Schupp, Marco, To, Christina, Locke, Frederick L.

Volltext

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma von Oluwole, Olalekan O., Bouabdallah, Krimo, Muñoz, Javier, De Guibert, Sophie, Vose, Julie M., Bartlett, Nancy L., Lin, Yi, Deol, Abhinav, McSweeney, Peter A., Goy, Andre H., Kersten, Marie José, Jacobson, Caron A., Farooq, Umar, Minnema, Monique C., Thieblemont, Catherine, Timmerman, John M., Stiff, Patrick, Avivi, Irit, Tzachanis, Dimitrios, Kim, Jenny J., Bashir, Zahid, McLeroy, Jeff, Zheng, Yan, Rossi, John M., Johnson, Lisa, Goyal, Lovely, Meerten, Tom

Volltext

At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies von Oluwole, Olalekan O., Davila, Marco L.

Volltext

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results von Shah, Bijal D., Bishop, Michael R., Oluwole, Olalekan O., Logan, Aaron C., Baer, Maria R., Donnellan, William B., O'Dwyer, Kristen M., Holmes, Houston, Arellano, Martha L., Ghobadi, Armin, Pagel, John M., Lin, Yi, Cassaday, Ryan D., Park, Jae H., Abedi, Mehrdad, Castro, Januario E., DeAngelo, Daniel J., Malone, Adriana K., Mawad, Raya, Schiller, Gary J., Rossi, John M., Bot, Adrian, Shen, Tong, Goyal, Lovely, Jain, Rajul K., Vezan, Remus, Wierda, William G.

Volltext